

Ashish Kumar Kakkar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1325889/publications.pdf>

Version: 2024-02-01

41
papers

786
citations

687363

13
h-index

526287

27
g-index

41
all docs

41
docs citations

41
times ranked

1514
citing authors

#	ARTICLE	IF	CITATIONS
1	Knowledge, attitude, and practice survey on antimicrobial use and resistance among Indian clinicians: A multicentric, cross-sectional study. <i>Perspectives in Clinical Research</i> , 2022, 13, 99.	1.0	8
2	Cefazolin Shortages in the Developing World: The Same, But Different Too. <i>Clinical Infectious Diseases</i> , 2021, 72, 1293-1295.	5.8	5
3	Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead. <i>European Journal of Pharmacology</i> , 2021, 890, 173717.	3.5	18
4	Minocycline for the management of multiple sclerosis: repositioning potential, opportunities, and challenges. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 35-43.	2.8	6
5	Deciphering the COVID-19 cytokine storm: Systematic review and meta-analysis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13429.	3.4	176
6	Assessment of Appropriateness of Antimicrobial Therapy in Resource-Constrained Settings: Development and Piloting of a Novel Tool—AmRAT. <i>Antibiotics</i> , 2021, 10, 200.	3.7	4
7	Pharmaceutical price regulation and its impact on drug innovation: mitigating the trade-offs. <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 189-192.	5.0	3
8	Concomitant use of dexamethasone and tetracyclines: a potential therapeutic option for the management of severe COVID-19 infection?. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 315-322.	3.1	3
9	System for administering and monitoring hydroxychloroquine prophylaxis for COVID-19 in accordance with a national advisory: preliminary experience of a tertiary care institute in India. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1331-1339.	4.4	3
10	Statins-induced hepatotoxicity: still more questions than answers. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1653-1654.	2.4	0
11	Impact of pharmaceutical price controls on the cost of cardiovascular drugs: does essentiality matter?. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 797-806.	3.1	2
12	Statin use and safety concerns: an overview of the past, present, and the future. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1011-1024.	2.4	15
13	Developing a latent class analysis model to identify at-risk populations among people using medicine without prescription. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1411-1422.	3.1	3
14	Antimicrobial Stewardship Programs in Resource Constrained Environments: Understanding and Addressing the Need of the Systems. <i>Frontiers in Public Health</i> , 2020, 8, 140.	2.7	51
15	Efficacy of anifrolumab in systemic lupus erythematosus: a critical analysis of the TULIP trials. <i>Lupus</i> , 2020, 29, 1002-1003.	1.6	3
16	Repurposing minocycline for COVID-19 management: mechanisms, opportunities, and challenges. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 997-1003.	4.4	22
17	Methodological Characteristics of Clinical Trials: Impact of Mandatory Trial Registration. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2019, 22, 131-141.	2.1	3
18	Decoding the Roadmap for Capacity Building of Pharmacology Academicians in Catering to Drug Information Center Services in a Developing Country. <i>Journal of Pharmacy Technology</i> , 2019, 35, 146-154.	1.0	8

#	ARTICLE	IF	CITATIONS
19	Satisfaction With Statin Treatment Among Adult Coronary Artery Disease Patients: An Experience From a Resource-Constrained Setting. <i>Heart Lung and Circulation</i> , 2019, 28, 1788-1794.	0.4	2
20	Ensuring access to "access"™ antibiotics: an imminent consideration for sustainable antimicrobial stewardship in the developing world. <i>Infectious Diseases</i> , 2019, 51, 395-398.	2.8	10
21	Posttrial Access to Medical Interventions: Intricacies, Challenges, and Solutions. <i>International Journal of Applied & Basic Medical Research</i> , 2019, 9, 3-8.	0.5	2
22	Statin related adverse effects and patient education: a study from resource limited settings. <i>Acta Cardiologica</i> , 2018, 73, 393-401.	0.9	9
23	Old wines in new bottles: Repurposing opportunities for Parkinson's disease. <i>European Journal of Pharmacology</i> , 2018, 830, 115-127.	3.5	15
24	Reporting of adverse drug reactions in India: A review of the current scenario, obstacles and possible solutions. <i>International Journal of Risk and Safety in Medicine</i> , 2018, 30, 33-44.	0.6	21
25	mHealth technologies in clinical trials: Opportunities and challenges. <i>Indian Journal of Pharmacology</i> , 2018, 50, 105.	0.7	12
26	Impact of regulatory spin of pioglitazone on prescription of antidiabetic drugs among physicians in India: A multicentre questionnaire-based observational study. <i>Indian Journal of Medical Research</i> , 2017, 146, 468-475.	1.0	3
27	The Promise of Dolutegravir: A Novel Second Generation Integrase Strand Transfer Inhibitor. <i>Current Clinical Pharmacology</i> , 2016, 11, 88-94.	0.6	7
28	Comparison of body composition in persons with epilepsy on conventional & new antiepileptic drugs. <i>Indian Journal of Medical Research</i> , 2016, 143, 323.	1.0	10
29	Effect of lamotrigine, levetiracetam & topiramate on neurobehavioural parameters & oxidative stress in comparison with valproate in rats. <i>Indian Journal of Medical Research</i> , 2016, 144, 104.	1.0	27
30	Patent cliff mitigation strategies: giving new life to blockbusters. <i>Expert Opinion on Therapeutic Patents</i> , 2015, 25, 1353-1359.	5.0	13
31	Drug treatment of obesity: Current status and future prospects. <i>European Journal of Internal Medicine</i> , 2015, 26, 89-94.	2.2	85
32	Management of Parkinson's disease: Current and future pharmacotherapy. <i>European Journal of Pharmacology</i> , 2015, 750, 74-81.	3.5	68
33	Obinutuzumab for chronic lymphocytic leukemia: promise of the first treatment approved with breakthrough therapy designation. <i>Journal of Oncology Pharmacy Practice</i> , 2015, 21, 358-363.	0.9	5
34	Current Issues With the Use of Bedaquiline. <i>Annals of Pharmacotherapy</i> , 2014, 48, 666-666.	1.9	3
35	Factors affecting choice of future specialty among medical students. <i>North American Journal of Medical Sciences</i> , 2014, 6, 181.	1.7	5
36	The Evolving Drug Development Landscape: From Blockbusters to Niche Busters in the Orphan Drug Space. <i>Drug Development Research</i> , 2014, 75, 231-234.	2.9	42

#	ARTICLE	IF	CITATIONS
37	GLP-1 receptor agonists and the risk of colorectal cancer. <i>Medical Hypotheses</i> , 2014, 82, 796.	1.5	0
38	Bedaquiline for the treatment of resistant tuberculosis: Promises and pitfalls. <i>Tuberculosis</i> , 2014, 94, 357-362.	1.9	95
39	India Puts Informed Consent on Camera. <i>Science</i> , 2014, 344, 150-151.	12.6	1
40	Effect of antiepileptic therapy on trace elements status in Indian population in a tertiary care hospital from northern India: A cross sectional study. <i>Epilepsy Research</i> , 2014, 108, 917-927.	1.6	17
41	Population Pharmacokinetics of Hydroxychloroquine Sulphate in Healthcare Workers Given for Prophylaxis Against Corona Virus Disease 2019 (COVID-19) in India. <i>Journal of Clinical Pharmacology</i> , 0, , .	2.0	1